charles r lacy

$huma

@jphailey1 @BioHarvestBHSC ilan is not getting his message across to wallstreet. the low volume tells me so but im still going to hold onto my shares and buy on dips. the technology is legit

@_chuck956 @BioHarvestBHSC I believe the focus is too directed towards current consumer products and less on the patented tech that could benefit God knows how many companies world wide…

NutritionInsight.com provides commentary on the announced partnership with Tate & Lyle, and cites other research in the sweetener space- Read article: bit.ly/40wjwcW

@MAGAQueenUSA liberals need to get over it, 78 million votes tells me so

Be honest Will you continue to support Carrie Underwood even though the liberals are going against her?

@MAGAVoice yes

Do you support Country Singer Carrie Underwood singing at President Trump’s inauguration ?

@jphailey1 @BioHarvestBHSC i agree with you there

@jphailey1 @BioHarvestBHSC i live this company also but the daily volume is horiffic in the stock

@BioHarvestBHSC I’m still convinced this is an early NVIDIA. The the pateneted technology they own is staggering in its long term potential. Recent guidance has this targeted for $12…

THERE SHE IS:) Carrie is a Patriot🇺🇸

BREAKING: Grammy Award-winning artist Carrie Underwood to perform ‘America the Beautiful’ at Trump’s inauguration.

Owner of the LA Times, Dr. Pat Soon-Shiong, now says that it was a "mistake" for his paper to endorse Karen Bass for Mayor in 2022: "Competence matters." Rick Caruso should run again, and win. Save LA!

$huma humacyte is a diamond in the rough and most of wallstreet doesnt even know it yet

Recently Laura Niklason, MD, PhD, CEO and Founder of Humacyte, Inc met with @Forbes to discuss our recent FDA approval of our Acellular Tissue Engineered Vessel (ATEV™) and its life saving possibilities. Every year, thousands of Americans receive traumatic injuries that damage the arteries that crucially carry blood to their limbs. When these occur, patients basically have three options: they can have a vein grafted from another part of their body, which takes extra time and causes additional trauma; the surgeon can replace the artery with a synthetic plastic one, which creates a high risk of infection; or the limb can be amputated." - Laura Niklason, CEO of Humacyte. But now, there's a fourth option! Humacyte's bioengineered human vessel, ATEV™, has been FDA-approved and offers a new solution to preserve limbs and potentially reduce infection risks. Read the Forbes’ article here: forbes.com/sites/alexknap… Learn more about ATEV here: bit.ly/atev_prod_huma For full Prescribing Information, including Boxed Warning click here: bit.ly/4dl5tuL #MedicineByDesign #RegenerativeMedicine #Innovation #Leadership #PatientImpact #Humacyte #Biotech #Forbes

@KylerJohnson411 i remember when cooper standard was a 150 dollar stock

Massive news for $CPS! #Autos #Stocks

@RevShark at 29,500 for the atev already tells me theres a big demand for the product otherwise the price would be cheaper

$HUMA update. Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma. DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced an update of plans for the commercial launch of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury. Humacyte is responding to requests for quotations from hospitals and has initiated the Value Analysis Committee approval processes at multiple hospitals as part of the preparation for market launch. The U.S. Food and Drug Administration (FDA) granted a full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible. Shortly after approval, Humacyte provided the final packaging and product batch release information required for FDA review prior to shipment of product. Humacyte currently expects to have authorization to commence product shipment early this quarter and continues to build product supply to support market launch. Humacyte has recruited and trained a highly experienced sales team for the commercial launch of Symvess. All ten sales team members are multi-year President’s Club winners, representing the top 10% of achievers in their prior sales organizations. All sales team members have demonstrated consistent overachievement with average hospital medical device and biotech experience exceeding 15 years. Each sales team member has experience in vascular surgery and/or trauma surgery, and 80% have previous experience selling regenerative therapies. All team members have experience selling clinically differentiated disruptive technologies and premium priced portfolios. Humacyte announced that the price of Symvess will be $29,500 per unit. The Company has developed a Budget Impact Model based on the clinical results supporting the approval of Symvess, and the estimated reduction in clinical complications potentially achievable by treating specific patients with Symvess versus current standard of care. Based on the model, the per-patient cost of treating patients with Symvess is estimated to be less than the cost of treating trauma patients with synthetic grafts, cryopreserved allografts, or xenografts. Major drivers of cost savings associated with Symvess were attributed to reductions in the rate of amputation and vascular conduit infection. Additionally, Humacyte submitted an NTAP (New Technology Add-On Payment) application for Symvess to CMS in October 2024. Humacyte presented the Symvess data at a public Town Hall with the Centers for Medicare and Medicaid Services (CMS) on December 11, 2024. If successful, NTAP reimbursement will start for discharges on October 1, 2025, offering hospitals additional payment to cover a portion of the costs associated with Symvess. “We are very excited to take the major steps in providing healthcare providers a novel alternative for treating patients suffering from extremity arterial injury,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “We are pleased to see interest from multiple hospitals and to have commenced the Value Analysis Committee approval processes. We look forward to the anticipated publication of our Budget Impact Model which highlights the major drivers of cost savings associated with Symvess and complement our strong clinical results.” Symvess, or the ATEV™ (acellular tissue engineered vessel), is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair. While harvesting vein from a trauma patient takes valuable surgical time and is not always feasible due to damage to veins or to the limbs, Symvess is available off-the-shelf, and does not require further injuring the patient to obtain vascular repair material. Humacyte’s BLA included positive results from the V005 pivotal Phase 2/3 clinical study, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program. Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds, and industrial accidents. It was utilized by vascular and trauma surgeons in Level 1 Trauma centers throughout the U.S. and Israel to repair severe limb-threatening and life-threatening injuries, and in front-line hospitals in Ukraine to treat wartime injuries. Results from these studies were published in JAMA Surgery on November 20, 2024. In the civilian and military clinical studies, Symvess was observed to have high rates of patency, or blood flow, and low rates of amputation and infection.

@beefwellingtoni THE 29,500 PRICE FOR THE ATEV TELLS ME THERE IS ALREADY A BIG DEMAND FOR THE PRODUCT OTHERWISE IT WOULD BE CHEAPER

I can assure you I do not have the influence that you are implying here Biotech is the most rate sensitive sector 10yr rocketing to 4.8% the past 3 weeks will do that for pre to small revenue companies

$huma SYMVESS priced at $29,500 when the highest estimate was $25,000. Should tell you something about early demand indications. investors.humacyte.com/news-releases/…

@moazzam0_reddit you got that right the price tells me a big demand for the ATEV

Adam Schiff was just elected to a six year term in the Senate. It explains a lot about California voters, doesn't it?

Tom Homan confirmed to NBC that President Trump's deportation forces will conduct workplace raids to round up illegal aliens. "You can count on worksite enforcement coming back." At this point, employers who hire illegals should just come clean and save themselves the embarrassment of ICE agents showing up to their factories, buildings, etc. Save us some resources by telling Homan exactly where they are.

Dj Akademiks tells Lebron james keep rapping to that Kendrick Lamar not like us calling Drake a pedo . You’ll be like Carmelo Anthony ringless when your wife Savannah James divorces you . When them white girls start exposing you

@DavidJHarrisJr i bet she voted democrat

This is Fran, and she lost her home in the California fires. She lived there for 26 years and lost everything. So devastating to see... Pray for Fran and everyone else that is being affected by these horrific events!🙏🙏